Regencell Bioscience
2 hedge funds and large institutions have $230K invested in Regencell Bioscience in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
2.04% less ownership
Funds ownership: 4.09% → 2.05% (-2%)
27% less capital invested
Capital invested by funds: $316K → $230K (-$86K)
33% less funds holding
Funds holding: 3 → 2 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$231K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$74K |
| 3 |
Morgan Stanley
New York
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $224K | +$157K | +259,008 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $6K | +$4.42K | +7,296 | New |
|
|
SSA
3
Schonfeld Strategic Advisors
New York
| – | -$231K | -387,600 | Closed |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| – | -$74K | -124,260 | Closed |
|
|
5
Morgan Stanley
New York
| – | -$11K | -19,114 | Closed |
|
RGC Hedge Fund Activity: Q4 2021 in Review
2 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q4 2021, worth a combined $230K — down 27% from $316K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RGC and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $157K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $231K sold.
- 2 institutional investors held Regencell Bioscience (RGC) as of Q4 2021, down from 3 in Q3 2021.
- Funds reported $230K of Regencell Bioscience stock for Q4 2021, down 27% quarter-over-quarter.
- 2 funds opened new Regencell Bioscience positions in Q4 2021 and 3 closed out, a net change of -1 holder.
- The largest Regencell Bioscience buyer in Q4 2021 was Geode Capital Management, an estimated $157K added.
- The largest Regencell Bioscience seller in Q4 2021 was Schonfeld Strategic Advisors, an estimated $231K sold.
Based on aggregated 13F filings for Q4 2021.